UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Differential diagnosis of myasthenia gravis

Author
Shawn J Bird, MD
Section Editors
Jeremy M Shefner, MD, PhD
Ira N Targoff, MD
Deputy Editor
John F Dashe, MD, PhD

INTRODUCTION

Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission. The hallmark of the disorder is a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles. Weakness is the result of an antibody-mediated, T-cell dependent immunological attack directed at proteins in the postsynaptic membrane of the neuromuscular junction (acetylcholine receptors or receptor-associated proteins). The diagnosis of MG can be established by clinical and serologic testing [1,2].

This topic will discuss the differential diagnosis of MG, including conditions that mimic ocular myasthenia and conditions that mimic generalized myasthenia. The diagnosis of MG is discussed separately, as are other aspects of this disorder. (See "Diagnosis of myasthenia gravis" and "Clinical manifestations of myasthenia gravis" and "Pathogenesis of myasthenia gravis" and "Treatment of myasthenia gravis".)

DIAGNOSIS OF MYASTHENIA GRAVIS

The diagnosis of MG is reviewed here briefly and discussed in detail elsewhere. (See "Diagnosis of myasthenia gravis".)

The optimal approach to the diagnosis of myasthenia gravis varies with the clinical setting. The first step is to establish that the symptoms and signs are consistent with myasthenia gravis and not another disorder. (See "Clinical manifestations of myasthenia gravis".)

The bedside ice pack test can be used to support the diagnosis of myasthenia gravis in patients with ptosis, but it is not helpful for those with extraocular muscle weakness. The edrophonium (Tensilon) test should be used only in those patients with obvious ptosis or ophthalmoparesis, in whom improvement after infusion of the drug can easily be observed. The sensitivity of the Tensilon test for the diagnosis of MG is in the range of 80 to 90 percent, but it is associated with many false-negative and false-positive results. (See "Diagnosis of myasthenia gravis", section on 'Bedside tests'.)

           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Sep 12 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol 2012; 32:215.
  2. Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 2010; 23:489.
  3. Mittag TW, Caroscio J. False-positive immunoassay for acetylcholine-receptor antibody in amyotrophic lateral sclerosis. N Engl J Med 1980; 302:868.
  4. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111 ( Pt 3):577.
  5. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332:1467.
  6. Vernino S, Adamski J, Kryzer TJ, et al. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 1998; 50:1806.
  7. Oh SJ. Myasthenia gravis Lambert-Eaton overlap syndrome. Muscle Nerve 2016; 53:20.
  8. Albers JW, Hodach RJ, Kimmel DW, Treacy WL. Penicillamine-associated myasthenia gravis. Neurology 1980; 30:1246.
  9. Adelman HM, Winters PR, Mahan CS, Wallach PM. D-penicillamine-induced myasthenia gravis: diagnosis obscured by coexisting chronic obstructive pulmonary disease. Am J Med Sci 1995; 309:191.
  10. Nogajski JH, Kiernan MC, Ouvrier RA, Andrews PI. Congenital myasthenic syndromes. J Clin Neurosci 2009; 16:1.
  11. Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord 2012; 22:99.
  12. Schara U, Della Marina A, Abicht A. Congenital myasthenic syndromes: current diagnostic and therapeutic approaches. Neuropediatrics 2012; 43:184.
  13. Garg N, Yiannikas C, Hardy TA, et al. Late presentations of congenital myasthenic syndromes: How many do we miss? Muscle Nerve 2016; 54:721.